Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 298 articles:
HTML format



Single Articles


    March 2024
  1. HONIG M, Altomare D, Caprioglio C, Collij L, et al
    Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
    Neurology. 2024;102:e208053.
    PubMed     Abstract available


  2. ACKLEY S, Calmasini C, Bouteloup V, Hill-Jarrett TG, et al
    Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.
    Neurology. 2024;102:e208054.
    PubMed     Abstract available


  3. GUO C, Harshfield EL, Markus HS
    Sleep Characteristics and Risk of Stroke and Dementia: An Observational and Mendelian Randomization Study.
    Neurology. 2024;102:e209141.
    PubMed     Abstract available


  4. FLEISHER AS, Munsie LM, Perahia DGS, Andersen SW, et al
    Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
    Neurology. 2024;102:e208061.
    PubMed     Abstract available


  5. CHRISTENSEN GM, Li Z, Liang D, Ebelt S, et al
    Association of PM(2.5) Exposure and Alzheimer Disease Pathology in Brain Bank Donors-Effect Modification by APOE Genotype.
    Neurology. 2024;102:e209162.
    PubMed     Abstract available


    February 2024
  6. HILL-JARRETT TG, Choi M, Buto PT, Miramontes S, et al
    Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing.
    Neurology. 2024;102:e208005.
    PubMed     Abstract available


  7. PASE MP, Himali JJ, Puerta R, Beiser AS, et al
    Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.
    Neurology. 2024;102:e208075.
    PubMed     Abstract available


  8. YASAR S, Nidadavolu L
    Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention.
    Neurology. 2024;102:e209180.
    PubMed    


  9. ADESUYAN M, Jani YH, Alsugeir D, Howard R, et al
    Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
    Neurology. 2024;102:e209131.
    PubMed     Abstract available


  10. SHINOTOH H
    White Matter Neuroinflammation Matters in Early Alzheimer Disease.
    Neurology. 2024;102:e208090.
    PubMed    


  11. HARDY J, Schott JM
    Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
    Neurology. 2024;102:e208096.
    PubMed     Abstract available


  12. LOOMIS SJ, Miller R, Castrillo-Viguera C, Umans K, et al
    Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
    Neurology. 2024;102:e207919.
    PubMed     Abstract available


  13. CHOLERTON B, Latimer CS, Crane PK, Corrada MM, et al
    Neuropathologic Burden and Dementia in Nonagenarians and Centenarians.
    Neurology. 2024;102:e208060.
    PubMed     Abstract available


  14. PARK SY, Setiawan VW, Crimmins EM, White LR, et al
    Racial and Ethnic Differences in the Population-Attributable Fractions of Alzheimer Disease and Related Dementias.
    Neurology. 2024;102:e208116.
    PubMed     Abstract available


  15. WANG Q, Schindler SE, Chen G, Mckay NS, et al
    Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
    Neurology. 2024;102:e208013.
    PubMed     Abstract available


  16. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
    Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
    Neurology. 2024;102:e208033.
    PubMed     Abstract available


    January 2024
  17. CASTILHOS RM, Snitz BE
    Longitudinal Cognitive Decline in Alzheimer Disease Prevention Trials.
    Neurology. 2024;102:e208067.
    PubMed     Abstract available


  18. DUBBELMAN MA, Hendriksen HMA, Harrison JE, Vijverberg EGB, et al
    Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.
    Neurology. 2024;102:e207978.
    PubMed     Abstract available


  19. LOPEZ OL, Villemagne VL, Chang YF, Cohen AD, et al
    Association Between beta-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia.
    Neurology. 2024;102:e207920.
    PubMed     Abstract available


  20. PEROSA V, Zanon Zotin MC, Schoemaker D, Sveikata L, et al
    Association Between Hippocampal Volumes and Cognition in Cerebral Amyloid Angiopathy.
    Neurology. 2024;102:e207854.
    PubMed     Abstract available


  21. ZANON ZOTIN MC, Makkinejad N, Schneider JA, Arfanakis K, et al
    Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample.
    Neurology. 2024;102:e207940.
    PubMed     Abstract available


    December 2023
  22. HANSEEUW BJ, Jacobs HIL, Schultz AP, Buckley RF, et al
    Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
    Neurology. 2023;101:e2533-e2544.
    PubMed     Abstract available


    November 2023
  23. ZHOU Z, Ryan J, Tonkin AM, Zoungas S, et al
    Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.
    Neurology. 2023;101:e2288-e2299.
    PubMed     Abstract available


  24. YOON SH, Kim HK, Lee JH, Chun JH, et al
    Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
    Neurology. 2023;101:e2162-e2171.
    PubMed     Abstract available


  25. FERGUSON EL, Zimmerman SC, Jiang C, Choi M, et al
    Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan.
    Neurology. 2023;101:e2172-e2184.
    PubMed     Abstract available


  26. NELSON PT, Jicha GA
    Early Hippocampal Atrophy Is an Important Signal for Clinicians, but Not Necessarily a Harbinger of Alzheimer Disease.
    Neurology. 2023 Nov 15:10.1212/WNL.0000000000208071.
    PubMed    


  27. PITTOCK RR, Aakre JA, Castillo AM, Ramanan VK, et al
    Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2023;101:e1837-e1849.
    PubMed     Abstract available


  28. HOWE MD, Rabinovici GD, Salloway SP
    Real-World Application of Anti-beta-Amyloid Monoclonal Antibodies: Untangling Eligibility.
    Neurology. 2023;101:811-812.
    PubMed    


    October 2023
  29. THEIS H, Bischof GN, Bruggemann N, Dargvainiene J, et al
    In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using (18)F-PI-2620 PET.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000207870.
    PubMed     Abstract available


  30. ALAM JJ, Maruff P, Doctrow SR, Chu HM, et al
    Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
    Neurology. 2023;101:e1708-e1717.
    PubMed     Abstract available


  31. SANTAMARIA BA, Corroza J, Sanchez-Ruiz de Gordoa J, Cabello C, et al
    Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease: A Potential Diagnostic Approach.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207865.
    PubMed     Abstract available


  32. STARK M, Wolfsgruber S, Kleineidam L, Frommann I, et al
    Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.
    Neurology. 2023 Oct 11:10.1212/WNL.0000000000207844.
    PubMed     Abstract available


  33. GONZALES MM, Vela G, Philip V, Trevino H, et al
    Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort.
    Neurology. 2023;101:e1531-e1541.
    PubMed     Abstract available


  34. OVEISGHARAN S, Yu L, Agrawal S, Nag S, et al
    Relation of Motor Impairments to Neuropathologic Changes of Limbic-Predominant Age-Related TDP-43 Encephalopathy in Older Adults.
    Neurology. 2023;101:e1542-e1553.
    PubMed     Abstract available


  35. BONOMI S, Samara A, Balestra N, Padalia A, et al
    Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-beta-Amyloid Monoclonal Antibody Treatment.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207927.
    PubMed    


  36. BRENNER S
    Reader Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:633-634.
    PubMed    


  37. OVEISGHARAN S, Bennett DA
    Author Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:634.
    PubMed    


  38. GANESH A, Galetta S
    Editors' Note: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:633.
    PubMed    


  39. LEWIS A, Gupta A, Oh I, Schindler SE, et al
    Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic.
    Neurology. 2023;101:e1424-e1433.
    PubMed     Abstract available


    September 2023
  40. GOODSMITH MS, Wroblewski KE, Schumm LP, McClintock MK, et al
    Association of APOE epsilon4 Status With Long-term Declines in Odor Sensitivity, Odor Identification, and Cognition in Older US Adults.
    Neurology. 2023;101:e1341-e1350.
    PubMed     Abstract available


  41. COOMANS EM, de Koning LA, Rikken RM, Verfaillie SC, et al
    Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207794.
    PubMed     Abstract available


  42. MALPETTI M, Rabinovici GD
    From Clinical Trials to Memory Clinics, tau-PET Visual Reads Can Help Diagnosis and Patient Stratification.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207935.
    PubMed    


  43. YAMAGUCHI S, Murakami T, Satoh M, Komiyama T, et al
    Associations of Dental Health With the Progression of Hippocampal Atrophy in Community-Dwelling Individuals: The Ohasama Study.
    Neurology. 2023;101:e1056-e1068.
    PubMed     Abstract available


    August 2023
  44. MONTEIRO C, Toth B, Brunstein F, Bobbala A, et al
    A Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants with Mild-to-Moderate Alzheimer's Disease (Lauriet).
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207663.
    PubMed     Abstract available


  45. EDLAND SD, Ucsd, Llibre-Guerra JJ
    Semorinemab in Mild to Moderate Alzheimer Disease: A Glimmer of Hope Though Cautions Remain.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207861.
    PubMed    


  46. KAMAL F, Morrison C, Maranzano J, Zeighami Y, et al
    White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment.
    Neurology. 2023;101:e815-e824.
    PubMed     Abstract available


  47. PARNETTI L, Bellomo G
    Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
    PubMed    


  48. KAWADA T
    Reader Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:333-334.
    PubMed    


  49. PROSSER L
    Author Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:334.
    PubMed    


  50. LEWIS A, Galetta S
    Editors' Note: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:333.
    PubMed    


  51. RAMANAN VK, Graff-Radford J, Syrjanen J, Shir D, et al
    Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
    Neurology. 2023 Aug 14:10.1212/WNL.0000000000207675.
    PubMed     Abstract available


  52. CATHARINA BOON BD, Labuzan S, Peng Z, Matchett B, et al
    Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared to Corticolimbic Alzheimer Disease Subtypes.
    Neurology. 2023 Aug 14:10.1212/WNL.0000000000207685.
    PubMed     Abstract available


  53. LAM AD
    Linking Late-Onset Epilepsy With Alzheimer Disease: Insights From Plasma Amyloid Measurements.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207683.
    PubMed    


  54. JOHNSON EL, Sullivan KJ, Schneider ALC, Simino J, et al
    Association of Plasma Abeta 42/40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207635.
    PubMed     Abstract available


  55. HADDAD A, Brunel G, Indart S, Paquet C, et al
    A Patient With the Posterior Variant of Alzheimer Disease Plays Table Tennis: Blindsight and Pingpong.
    Neurology. 2023 Aug 3:10.1212/WNL.0000000000207650.
    PubMed    


    July 2023
  56. DURCAN R, Roberts G, Hamilton CA, Donaghy PC, et al
    Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls.
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207621.
    PubMed     Abstract available


  57. RAMANAN VK, Armstrong MJ, Choudhury P, Coerver K, et al
    Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.
    Neurology. 2023 Jul 26:10.1212/WNL.0000000000207757.
    PubMed     Abstract available


  58. PROKOPIOU PC, Engels-Dominguez N, Schultz AP, Sepulcre J, et al
    Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease.
    Neurology. 2023 Jul 25:10.1212/WNL.0000000000207646.
    PubMed     Abstract available


  59. KARCESKI S, Antonopoulos M
    Biomarkers in Alzheimer Disease: A Review.
    Neurology. 2023;101:e461-e463.
    PubMed    


  60. ANDRE C, Kuhn E, Rehel S, Ourry V, et al
    Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults.
    Neurology. 2023;101:e370-e385.
    PubMed     Abstract available


  61. ALCOLEA D, Beeri MS, Rojas JC, Gardner RC, et al
    Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
    Neurology. 2023;101:172-180.
    PubMed     Abstract available


  62. BURKE JF, Richard S, Langa KM, Albin RL, et al
    Lecanemab: Looking Before We Leap.
    Neurology. 2023 Jul 21:10.1212/WNL.0000000000207505.
    PubMed     Abstract available


  63. SHIR D, Pham NTT, Botha H, Koga S, et al
    Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome.
    Neurology. 2023;101:e289-e299.
    PubMed     Abstract available


  64. DITTRICH A, Ashton NJ, Zetterberg H, Blennow K, et al
    Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg.
    Neurology. 2023;101:e277-e288.
    PubMed     Abstract available


  65. MOSER ED, Manemann SM, Larson NB, St Sauver JL, et al
    Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease Related Dementias.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207595.
    PubMed     Abstract available


  66. BARBA L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, et al
    CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
    Neurology. 2023;101:e50-e62.
    PubMed     Abstract available


  67. FERREIRA PCL, Ferrari-Souza JP, Tissot C, Bellaver B, et al
    Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
    Neurology. 2023;101:38-45.
    PubMed     Abstract available


  68. LICHTER DG, Hershey L
    Proposal to Add FDG-PET as an Outcome Measure for Clinical Trials in Patients With Prodromal Lewy Body Dementia.
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207498.
    PubMed    


    June 2023
  69. KNOPMAN DS, Hershey L
    Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift.
    Neurology. 2023 Jun 9:10.1212/WNL.0000000000207438.
    PubMed     Abstract available


    May 2023
  70. GROBER E, Petersen KK, Lipton RB, Hassenstab J, et al
    Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.
    Neurology. 2023;100:e2279-e2289.
    PubMed     Abstract available


  71. FANG Y, Si X, Wang J, Wang Z, et al
    Alzheimer Disease and Epilepsy: A Mendelian Randomization Study.
    Neurology. 2023 May 24:10.1212/WNL.0000000000207423.
    PubMed     Abstract available


  72. LUO J, Ma Y, Agboola FJ, Grant E, et al
    Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Lifespan.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207378.
    PubMed     Abstract available


  73. DIAZ-GALVAN P, Przybelski SA, Lesnick TG, Schwarz CG, et al
    beta-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207393.
    PubMed     Abstract available


  74. ALVES F, Kalinowski P, Ayton S
    Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: A Systematic Review and Meta-analysis.
    Neurology. 2023;100:e2114-e2124.
    PubMed     Abstract available


  75. DU J, Li A, Shi D, Chen X, et al
    Association of APOE4, Osteoarthritis, beta-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory Regions in Alzheimer Disease.
    Neurology. 2023 May 15:10.1212/WNL.0000000000207369.
    PubMed     Abstract available


  76. BUTLER PAGNOTTI RM, Pudumjee SB, Cross CL, Miller JB, et al
    Cognitive and Clinical Characteristics of Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy.
    Neurology. 2023;100:e2027-e2035.
    PubMed     Abstract available


  77. CICOGNOLA C, Mattsson-Carlgren N, van Westen D, Zetterberg H, et al
    Associations of CSF PDGFRbeta With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
    Neurology. 2023 May 3:10.1212/WNL.0000000000207358.
    PubMed     Abstract available


  78. SINHA N, Gugger JJ
    Towards a Patient-Specific Readout of Neurodegeneration: The Case for Spatial Normative Modeling in Alzheimer Disease.
    Neurology. 2023 May 1:10.1212/WNL.0000000000207280.
    PubMed    


  79. VERDI S, Kia SM, Yong KXX, Tosun D, et al
    Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling.
    Neurology. 2023 May 1:10.1212/WNL.0000000000207298.
    PubMed     Abstract available


    April 2023
  80. GERTJE EC, Janelidze S, van Westen D, Cullen N, et al
    Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
    Neurology. 2023;100:e1812-e1824.
    PubMed     Abstract available


  81. KUHN E, Perrotin A, La Joie R, Touron E, et al
    Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
    Neurology. 2023 Apr 21:10.1212/WNL.0000000000207338.
    PubMed     Abstract available


  82. INSEL PS, Kumar A, Hansson O, Mattsson-Carlgren N, et al
    Genetic Moderation of the Association of beta-Amyloid With Cognition and MRI in Alzheimer Disease.
    Neurology. 2023 Apr 21:10.1212/WNL.0000000000207305.
    PubMed     Abstract available


  83. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
    Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
    Neurology. 2023;100:e1691-e1701.
    PubMed     Abstract available


  84. YANG Z, Wei C, Li X, Yuan J, et al
    Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants.
    Neurology. 2023;100:e1702-e1711.
    PubMed     Abstract available


  85. TIAN J, Raghavan Pillai SK, Reid RI, Przybelski SA, et al
    White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease.
    Neurology. 2023 Apr 17:10.1212/WNL.0000000000207250.
    PubMed     Abstract available


  86. BRODTMANN A, Beversdorf DQ
    The Alzheimer Disconnectome.
    Neurology. 2023 Apr 17:10.1212/WNL.0000000000207303.
    PubMed    



  87. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-Amyloid Immunotherapy: A Meta-analysis.
    Neurology. 2023 Apr 4:10.1212/WNL.0000000000207344.
    PubMed    


  88. WANG Y, Liang J, Fang Y, Yao D, et al
    Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: An Analysis for the Global Burden of Disease Study 2019.
    Neurology. 2023 Apr 4:10.1212/WNL.0000000000207218.
    PubMed     Abstract available


    March 2023
  89. BARKHOF F, Knopman DS
    Brain Shrinkage in Anti-beta-Amyloid Alzheimer Trials: Neurodegeneration or Pseudo-atrophy?
    Neurology. 2023 Mar 27:10.1212/WNL.0000000000207268.
    PubMed    


  90. ZHANG Y, Liu X, Wiggins KL, Kurniansyah N, et al
    Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts.
    Neurology. 2023 Mar 16:10.1212/WNL.0000000000207157.
    PubMed     Abstract available


  91. AGARWAL P, Leurgans SE, Agrawal S, Aggarwal N, et al
    Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology.
    Neurology. 2023 Mar 8:10.1212/WNL.0000000000207176.
    PubMed     Abstract available


  92. KURIHARA M, Komatsu H, Sengoku R, Shibukawa M, et al
    CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
    Neurology. 2023;100:e1009-e1019.
    PubMed     Abstract available


  93. CHAPMAN S, Renteria MA, Dworkin JD, Garriga SM, et al
    Association of Subjective Cognitive Decline With Progression to Dementia in a Cognitively Unimpaired Multiracial Community Sample.
    Neurology. 2023;100:e1020-e1027.
    PubMed     Abstract available


    February 2023
  94. TIAN Q, An Y, Kitner-Triolo MH, Davatzikos C, et al
    Associations of Olfaction With Longitudinal Trajectories of Brain Volumes and Neuropsychological Function in Older Adults.
    Neurology. 2023;100:e964-e974.
    PubMed     Abstract available


  95. SARTO J, Ruiz-Garcia R, Guillen N, Ramos-Campoy O, et al
    Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
    Neurology. 2023;100:e860-e873.
    PubMed     Abstract available


  96. FERREIRA D, Przybelski SA, Lesnick TG, Schwarz CG, et al
    Cross-sectional Associations of beta-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies.
    Neurology. 2023;100:e846-e859.
    PubMed     Abstract available


  97. MCCUSKER EA, Loy CT
    Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers.
    Neurology. 2023 Feb 15:10.1212/WNL.0000000000207199.
    PubMed    


  98. GECZI K
    Right Brain: Oriented to Self.
    Neurology. 2023;100:349-350.
    PubMed     Abstract available


    January 2023
  99. LARGENT EA, Grill J, O'Brien K, Wolk D, et al
    Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
    Neurology. 2023 Jan 31:10.1212/WNL.0000000000206891.
    PubMed     Abstract available


  100. OVEISGHARAN S, Yang J, Yu L, Burba D, et al
    Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023 Jan 25:10.1212/WNL.0000000000206833.
    PubMed     Abstract available



  101. Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease.
    Neurology. 2023 Jan 24:10.1212/WNL.0000000000201690.
    PubMed    



  102. Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
    Neurology. 2023 Jan 23:10.1212/WNL.0000000000206876.
    PubMed    


  103. OHRFELT A, Benedet AL, Ashton NJ, Kvartsberg H, et al
    Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
    Neurology. 2023;100:e275-e285.
    PubMed     Abstract available


  104. ALTY JE, Bindoff AD, Stuart KE, Roccati E, et al
    Sex-Specific Protective Effects of Cognitive Reserve on Age-Related Cognitive Decline: A 5-Year Prospective Cohort Study.
    Neurology. 2023;100:e211-e219.
    PubMed     Abstract available


  105. SAJJADI SA, Bukhari S, Scambray KA, Yan R, et al
    Impact and Risk Factors of Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Change in an Oldest-Old Cohort.
    Neurology. 2023;100:e203-e210.
    PubMed     Abstract available


  106. GLANS I, Sonestedt E, Nagga K, Gustavsson AM, et al
    Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period.
    Neurology. 2023;100:e28-e37.
    PubMed     Abstract available


    December 2022
  107. BARRIO IR, Miki Y, Jaunmuktane ZT, Warner T, et al
    Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
    Neurology. 2022 Dec 16:10.1212/WNL.0000000000201659.
    PubMed     Abstract available


    November 2022
  108. RAJAN K, McAninch EA, Aggarwal N, Barnes LL, et al
    Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample.
    Neurology. 2022 Nov 29:10.1212/WNL.0000000000201289.
    PubMed     Abstract available


  109. HUANG J, Su B, Karhunen V, Gill D, et al
    Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization.
    Neurology. 2022 Nov 16. pii: WNL.0000000000201489.
    PubMed     Abstract available


  110. ROYALL DR
    Reader Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918-919.
    PubMed    


  111. GANESH A, Galetta S
    Editors' Note: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918.
    PubMed    


  112. QIU WQ, Tao Q, Akhter-Khan SC
    Author Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:919.
    PubMed    


  113. YU L, Hsieh YC, Pearse RV, Wang Y, et al
    Association of AK4 Protein From Stem Cell-Derived Neurons With Cognitive Reserve: An Autopsy Study.
    Neurology. 2022;99:e2264-e2274.
    PubMed     Abstract available


  114. PROSSER L, MacDougall A, Sudre CH, Manning EN, et al
    Predicting Cognitive Decline in Nondemented Elders Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2022 Nov 10. pii: WNL.0000000000201572.
    PubMed     Abstract available


  115. ROSENBERG A, Ohlund-Wistbacka U, Hall A, Bonnard A, et al
    beta-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
    Neurology. 2022;99:e2102-e2113.
    PubMed     Abstract available


  116. TANGEN GG, Nilsson MH, Stomrud E, Palmqvist S, et al
    Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.
    Neurology. 2022;99:e2081-e2091.
    PubMed     Abstract available


  117. GHAHREMANI M, Wang M, Chen HY, Zetterberg H, et al
    Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease.
    Neurology. 2022 Nov 2. pii: WNL.0000000000201517.
    PubMed     Abstract available


    October 2022
  118. MICHIELS L, Thijs L, Mertens N, Sunaert S, et al
    In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke.
    Neurology. 2022 Oct 27. pii: WNL.0000000000201344.
    PubMed     Abstract available


  119. SUCHY-DICEY AM, Oziel K, Sawyer C, Olufadi Y, et al
    Educational and Clinical Associations With Longitudinal Cognitive Function and Brain Imaging in American Indians: The Strong Heart Study.
    Neurology. 2022 Oct 26. pii: WNL.0000000000201261.
    PubMed     Abstract available


  120. QUISPIALAYA KM, Therriault J, Aliaga A, Zimmermann M, et al
    Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.
    Neurology. 2022 Oct 20. pii: WNL.0000000000201198.
    PubMed     Abstract available


  121. PLANCHE V, Bouteloup V, Pellegrin I, Mangin JF, et al
    Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
    Neurology. 2022 Oct 19. pii: WNL.0000000000201479.
    PubMed     Abstract available


  122. GREENBERG BD, Pettigrew C, Soldan A, Wang J, et al
    CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4.
    Neurology. 2022;99:e1640-e1650.
    PubMed     Abstract available


    September 2022

  123. Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
    Neurology. 2022 Sep 30. pii: WNL.0000000000201298.
    PubMed    


  124. GALE SA, Heidebrink J, Grill J, Graff-Radford J, et al
    Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.
    Neurology. 2022 Sep 30. pii: WNL.0000000000201347.
    PubMed     Abstract available


  125. BEVERSDORF DQ, Scharre DW
    The Dilemma of the Clinical Utility of Alzheimer Biomarker Evaluation in Everyday Clinical Practice: My Favorite PETs.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201478.
    PubMed    


  126. ROMERO JR, Pinheiro A, Aparicio HJ, DeCarli CS, et al
    MRI Visible Perivascular Spaces and Risk of Incident Dementia: The Framingham Heart Study.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201293.
    PubMed     Abstract available


  127. DEMNITZ-KING H, Gonneaud J, Klimecki OM, Chocat A, et al
    Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults.
    Neurology. 2022;99:e1422-e1431.
    PubMed     Abstract available


  128. SUGDEN K, Caspi A, Elliott ML, Bourassa KJ, et al
    Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia.
    Neurology. 2022;99:e1402-e1413.
    PubMed     Abstract available


  129. CONSTANT AB, Basavaraju R, France J, Honig LS, et al
    Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology.
    Neurology. 2022 Sep 19. pii: WNL.0000000000200947.
    PubMed     Abstract available


  130. KAMAGATA K, Andica C, Takabayashi K, Saito Y, et al
    Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
    Neurology. 2022 Sep 19. pii: WNL.0000000000201300.
    PubMed     Abstract available


  131. HICKS AJ, Ponsford JL, Spitz G, Dore V, et al
    beta-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study.
    Neurology. 2022;99:e1131-e1141.
    PubMed     Abstract available


  132. ZETTERBERG H, Schott JM
    Objectifying Subjective Cognitive Decline: The Prognostic Role of Alzheimer Biomarkers.
    Neurology. 2022 Sep 2. pii: WNL.0000000000201172.
    PubMed    


    August 2022
  133. QUILICO COUSINS KA, Arezoumandan S, Shellikeri S, Ohm D, et al
    CSF Biomarkers of Alzheimer Disease in Patients With Concomitant alpha-Synuclein Pathology.
    Neurology. 2022 Aug 30. pii: WNL.0000000000201202.
    PubMed     Abstract available


  134. DUBBELMAN MA, Verrijp M, Terwee CB, Jutten RJ, et al
    Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness.
    Neurology. 2022;99:e954-e964.
    PubMed     Abstract available


  135. JEONG SY, Suh CH, Shim WH, Lim JS, et al
    Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-amyloid Immunotherapy: A Meta-analysis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201019.
    PubMed     Abstract available


  136. SALMON DP, Smirnov DS, Coughlin DG, Hamilton JM, et al
    Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease.
    Neurology. 2022 Aug 26. pii: WNL.0000000000201068.
    PubMed     Abstract available


  137. ROSTAMZADEH A, Bohr L, Wagner M, Baethge C, et al
    Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-Analysis.
    Neurology. 2022 Aug 26. pii: WNL.0000000000201072.
    PubMed     Abstract available


  138. BILLETTE OV, Ziegler G, Aruci M, Schutze H, et al
    Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease.
    Neurology. 2022;99:e775-e788.
    PubMed     Abstract available


  139. JEONG SH, Cha J, Park M, Jung JH, et al
    Association of Enlarged Perivascular Spaces With Amyloid Burden and Cognitive Decline in Alzheimer Disease Continuum.
    Neurology. 2022 Aug 19. pii: WNL.0000000000200989.
    PubMed     Abstract available


  140. DUMURGIER J, Sabia S, Zetterberg H, Teunissen CE, et al
    A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
    Neurology. 2022;99:e669-e678.
    PubMed     Abstract available


  141. GILL D, Vujkovic M
    The Potential of Genetic Data for Prioritizing Drug Repurposing Efforts.
    Neurology. 2022;99:267-268.
    PubMed    


  142. CROTTY GF, Keavney JL, Alcalay RN, Marek K, et al
    Planning for Prevention of Parkinson Disease: Now Is the Time.
    Neurology. 2022;99.
    PubMed     Abstract available


  143. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
    Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
    Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
    PubMed     Abstract available


  144. AKINCI M, Pena-Gomez C, Operto G, Fuentes-Julian S, et al
    Pre-pandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200948.
    PubMed     Abstract available


  145. CEDRES N, Ferreira D, Nemy M, Machado A, et al
    Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200930.
    PubMed     Abstract available


    July 2022
  146. SHAHIM P, Zetterberg H, Simren J, Ashton NJ, et al
    Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes.
    Neurology. 2022;99:e347-e354.
    PubMed     Abstract available


  147. SCHINDLER SE, Karikari TK, Ashton NJ, Henson RL, et al
    Effect of Race on Prediction of Brain Amyloidosis by Plasma Abeta42/Abeta40, Phosphorylated Tau, and Neurofilament Light.
    Neurology. 2022;99:e245-e257.
    PubMed     Abstract available


  148. BORLAND E, Edgar C, Stomrud E, Cullen N, et al
    Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
    Neurology. 2022 Jul 14. pii: WNL.0000000000200817.
    PubMed     Abstract available


  149. WYNN M
    My First Patient With Alzheimer's.
    Neurology. 2022 Jul 14. pii: WNL.0000000000201087.
    PubMed    


  150. KEUSS SE, Coath W, Nicholas JM, Poole T, et al
    Associations of beta-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort.
    Neurology. 2022;99:e129-e141.
    PubMed     Abstract available


    June 2022
  151. MONTINE TJ, Corrada MM, Kawas C, Bukhari S, et al
    Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old.
    Neurology. 2022 Jun 15. pii: WNL.0000000000200832.
    PubMed     Abstract available


  152. PETERSEN KK, Lipton RB, Grober E, Davatzikos C, et al
    Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data.
    Neurology. 2022;98:e2425-e2435.
    PubMed     Abstract available


  153. YANG JJ, Keohane LM, Pan X, Qu R, et al
    Association of Healthy Lifestyles with Risk of Alzheimer Disease and Related Dementias in Low-Income Black and White Americans.
    Neurology. 2022 Jun 13. pii: WNL.0000000000200774.
    PubMed     Abstract available


  154. TANG B, Wang Y, Jiang X, Thambisetty M, et al
    Genetic Variation in Targets of Anti-diabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.
    Neurology. 2022 Jun 2. pii: WNL.0000000000200771.
    PubMed     Abstract available


    May 2022
  155. KUMAR A, Janelidze S, Stomrud E, Palmqvist S, et al
    beta-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
    Neurology. 2022 May 31. pii: WNL.0000000000200605.
    PubMed     Abstract available


  156. DUMURGIER J, Sabia S, Zetterberg H, Teunissen C, et al
    Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
    Neurology. 2022 May 26. pii: WNL.0000000000200735.
    PubMed     Abstract available


  157. MOHANTY R, Ferreira D, Frerich S, Muehlboeck JS, et al
    Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
    Neurology. 2022 May 24. pii: WNL.0000000000200573.
    PubMed     Abstract available


  158. MCGIRR A, Nathan S, Ghahremani M, Gill S, et al
    Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms.
    Neurology. 2022;98:e2132-e2139.
    PubMed     Abstract available


  159. XICOTA L, Gyorgy B, Grenier-Boley B, Lecoeur A, et al
    Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults.
    Neurology. 2022 May 23. pii: WNL.0000000000200544.
    PubMed     Abstract available


  160. TOLLER G, Cobigo Y, Ljubenkov PA, Appleby BS, et al
    Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia.
    Neurology. 2022 May 18. pii: WNL.0000000000200582.
    PubMed     Abstract available


  161. FARNSWORTH VON CEDERWALD B, Josefsson M, Wahlin A, Nyberg L, et al
    Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia.
    Neurology. 2022;98:e2013-e2022.
    PubMed     Abstract available


  162. LI Z, Heckman MG, Kanekiyo T, Martens YA, et al
    Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment.
    Neurology. 2022;98:e2036-e2045.
    PubMed     Abstract available


  163. ASKEN BM, Tanner JA, VandeVrede L, Mantyh WG, et al
    Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Neurology. 2022 May 16. pii: WNL.0000000000200678.
    PubMed     Abstract available


  164. AGOSTA F, Filippi M
    Natural Speech Analysis: A Window Into Alzheimer Disease Phenotypes.
    Neurology. 2022 May 4. pii: WNL.0000000000200843.
    PubMed    


  165. BEYDOUN MA, Beydoun HA, Fanelli-Kuczmarski MT, Weiss J, et al
    Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults.
    Neurology. 2022 May 4. pii: WNL.0000000000200289.
    PubMed     Abstract available


    April 2022
  166. CHO S, Quilico Cousins KA, Shellikeri S, Ash S, et al
    Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology.
    Neurology. 2022 Apr 29. pii: WNL.0000000000200581.
    PubMed     Abstract available


  167. WHITWELL J, Martin PR, Graff-Radford J, Machulda M, et al
    Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200336.
    PubMed     Abstract available


  168. VOGEL JW, Tosun D
    Multiple Cortical to Striatal Accumulation Trajectories of beta-Amyloid: Do All Roads Lead to Rome?
    Neurology. 2022;98:695-696.
    PubMed    


  169. COLLIJ LE, Salvado G, Wottschel V, Mastenbroek SE, et al
    Spatial-Temporal Patterns of beta-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis.
    Neurology. 2022;98:e1692-e1703.
    PubMed     Abstract available


  170. BEAUDIN AE, McCreary CR, Mazerolle EL, Gee M, et al
    Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy.
    Neurology. 2022;98:e1716-e1728.
    PubMed     Abstract available


  171. ARANHA MR, Fortea J, Carmona-Iragui M
    Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease.
    Neurology. 2022 Apr 25. pii: WNL.0000000000200704.
    PubMed    


  172. FRANK B, Ally M, Tripodis Y, Puzo C, et al
    Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease.
    Neurology. 2022 Apr 20. pii: WNL.0000000000200304.
    PubMed     Abstract available


  173. BEAMAN C, Kozii K, Hilal S, Liu M, et al
    Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration.
    Neurology. 2022;98:e1605-e1616.
    PubMed     Abstract available


  174. DIFRANCESCO JC, Stanzani L
    Increased Brain Volume: A Novel Biomarker of Neurodegeneration?
    Neurology. 2022;98:649-650.
    PubMed    


  175. SIBLE IJ, Nation DA
    Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200302.
    PubMed     Abstract available


  176. GRAFF-RADFORD J, Josephs K
    Author Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:644.
    PubMed    


  177. DASHEIFF R
    Reader Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:643.
    PubMed    


  178. SIEGLER JE 3RD, Galetta S
    Editors' Note: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:643.
    PubMed    


  179. FARRELL ME, Papp KV, Buckley RF, Jacobs HIL, et al
    Association of Emerging beta-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.
    Neurology. 2022;98:e1512-e1524.
    PubMed     Abstract available


  180. TIDEMAN P, Stomrud E, Leuzy A, Mattsson-Carlgren N, et al
    Association of beta-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
    Neurology. 2022;98:e1525-e1533.
    PubMed     Abstract available


  181. GAUTHREAUX KM, Teylan MA, Katsumata Y, Mock C, et al
    Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis.
    Neurology. 2022;98:e1422-e1433.
    PubMed     Abstract available


  182. GU Y, Kociolek A, Fernandez KK, Cosentino SA, et al
    Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes.
    Neurology. 2022 Apr 4. pii: WNL.0000000000200259.
    PubMed     Abstract available


    March 2022
  183. GUAN Y, Ebrahimzadeh SA, Cheng CH, Chen W, et al
    Association of Diabetes and Hypertension With Brain Structural Integrity and Cognition in the Boston Puerto Rican Health Study Cohort.
    Neurology. 2022 Mar 30. pii: WNL.0000000000200120.
    PubMed     Abstract available


  184. ZAMMIT AR, Yu L, Petyuk V, Schneider JA, et al
    Cortical Proteins and Individual Differences in Cognitive Resilience in Older Adults.
    Neurology. 2022;98:e1304-e1314.
    PubMed     Abstract available


  185. SALINAS J, Beiser AS, Samra JK, O'Donnell A, et al
    Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline.
    Neurology. 2022;98:e1337-e1348.
    PubMed     Abstract available


  186. PETERSEN RC
    Detecting Alzheimer Disease Clinically: How Early Can We Go?
    Neurology. 2022 Mar 25. pii: WNL.0000000000200172.
    PubMed    


  187. VAN DE BEEK M, Ooms FAH, Ebenau JL, Barkhof F, et al
    Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
    Neurology. 2022;98:e1262-e1272.
    PubMed     Abstract available


  188. VAN LOENHOUD AC, Groot C, Bocancea DI, Barkhof F, et al
    Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200116.
    PubMed     Abstract available


  189. JOSEPHS KA, Weigand SD, Whitwell J
    Characterizing Amyloid Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200287.
    PubMed     Abstract available


  190. HESHMATOLLAH A, Fani L, Koudstaal PJ, Ghanbari M, et al
    Plasma Amyloid Beta, Total-Tau and Neurofilament Light Chain Levels and the Risk of Stroke: A Prospective Population-Based Study.
    Neurology. 2022 Mar 1. pii: WNL.0000000000200004.
    PubMed     Abstract available


    February 2022
  191. DAY GS, Scarmeas N, Dubinsky R, Coerver K, et al
    Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee.
    Neurology. 2022 Feb 23. pii: WNL.0000000000200176.
    PubMed     Abstract available


  192. GROBER E, Lipton RB, Sperling RA, Papp KV, et al
    Associations of Stages of Objective Memory Impairment (SOMI) with Amyloid PET and Structural MRI: The A4 Study.
    Neurology. 2022 Feb 23. pii: WNL.0000000000200046.
    PubMed     Abstract available


  193. MATTSSON-CARLGREN N, Grinberg LT, Boxer A, Ossenkoppele R, et al
    Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Neurology. 2022 Feb 16. pii: WNL.0000000000200040.
    PubMed     Abstract available


  194. CHU WT, Wang WE, Zaborszky L, Golde TE, et al
    Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract.
    Neurology. 2022;98:e700-e710.
    PubMed     Abstract available


  195. EBENAU JL, Pelkmans W, Verberk IMW, Verfaillie S, et al
    Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
    Neurology. 2022 Feb 2. pii: WNL.0000000000200035.
    PubMed     Abstract available


    January 2022
  196. BOWN CW, Carare RO, Schrag MS, Jefferson AL, et al
    Physiology and Clinical Relevance of Enlarged Perivascular Spaces in the Aging Brain.
    Neurology. 2022;98:107-117.
    PubMed     Abstract available


  197. WHITTINGTON MD, Campbell JD, Rind D, Fluetsch N, et al
    Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
    Neurology. 2022 Jan 12. pii: WNL.0000000000013314.
    PubMed     Abstract available


  198. BALLARINI T, Melo van Lent D, Wagner M
    Author Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:89-90.
    PubMed    


  199. GANESH A, Galetta S
    Editors' Note: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:88.
    PubMed    


  200. BRENNER SR
    Reader Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:88-89.
    PubMed    


  201. DA SILVA SOYOMBO NK, Rocha EL, Xavier LB, Oliveira RA, et al
    Biomarkers for Differential Diagnosis Between Chronic Traumatic Encephalopathy and Alzheimer Disease: A Systematic Review.
    Neurology. 2022;98.
    PubMed     Abstract available


    December 2021
  202. YOO HS, Jeon S, Cavedo E, Ko M, et al
    Association of beta-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.
    Neurology. 2021 Dec 30. pii: WNL.0000000000013277.
    PubMed     Abstract available


  203. CULLEN N, Janelidze S, Palmqvist S, Stomrud E, et al
    Association of CSF Abeta38 Levels With Risk of Alzheimer Disease-Related Decline.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013228.
    PubMed     Abstract available


  204. YU L, Boyle PA, Wingo AP, Yang J, et al
    Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013252.
    PubMed     Abstract available


  205. LI Y, Schindler SE, Bollinger JG, Ovod V, et al
    Validation of Plasma Amyloid-beta 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
    Neurology. 2021 Dec 14. pii: WNL.0000000000013211.
    PubMed     Abstract available


    November 2021
  206. SMIRNOV DS, Salmon DP, Galasko D, Goodwill VS, et al
    Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study.
    Neurology. 2021 Nov 22. pii: WNL.0000000000013107.
    PubMed     Abstract available


  207. ACOSTA LM
    I Wasn't There: Caring for a Patient With Trisomy 21, Alzheimer Disease, and Epilepsy Until His Final Days With COVID-19.
    Neurology. 2021 Nov 22. pii: WNL.0000000000013109.
    PubMed     Abstract available


  208. CHIONG W, Tolchin BD, Bonnie RJ, Busl K, et al
    Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement.
    Neurology. 2021 Nov 17. pii: WNL.0000000000013053.
    PubMed    


  209. KUSCHPEL MS
    Reader Response: Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Neurology. 2021;97:964-965.
    PubMed    


  210. SCHELBAUM E, Loughlin L, Jett S, Zang C, et al
    Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife.
    Neurology. 2021 Nov 3. pii: WNL.0000000000012941.
    PubMed     Abstract available


    October 2021
  211. LEUZY A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al
    Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Neurology. 2021;97:e1681-e1694.
    PubMed     Abstract available


    September 2021
  212. KIM YJ, Karceski S
    Alzheimer Disease and Mood.
    Neurology. 2021;97:e1363-e1366.
    PubMed    


  213. EDMONDS EC, Smirnov DS, Thomas KR, Graves LV, et al
    Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.
    Neurology. 2021;97:e1288-e1299.
    PubMed     Abstract available


  214. MILA-ALOMA M, Brinkmalm A, Ashton NJ, Kvartsberg H, et al
    CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012853.
    PubMed     Abstract available


  215. GARNIER-CRUSSARD A, Krolak-Salmon P
    Reader Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;97:608.
    PubMed    


  216. THERRIAULT J, Pascoal T, Gauthier S, Rosa-Neto P, et al
    Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;97:609.
    PubMed    


  217. JEONG SH, Kim HR, Kim J, Kim H, et al
    Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment.
    Neurology. 2021;97:e1110-e1122.
    PubMed     Abstract available


  218. HERSHEY LA, Tarawneh R
    Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
    Neurology. 2021;97:517-518.
    PubMed    


  219. SCHINDLER S, Li Y, Buckles VD, Gordon BA, et al
    Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012775.
    PubMed     Abstract available


  220. BUCIUC M, Josephs KA, Jones DT, Whitwell JL, et al
    Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012783.
    PubMed    


  221. MCCARTER S, Lesnick TG, Lowe V, Mielke MM, et al
    Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-beta PET Signal.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012770.
    PubMed     Abstract available


    August 2021
  222. FRISON E, Proust-Lima C, Mangin JF, Habert MO, et al
    Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort.
    Neurology. 2021;97:e836-e848.
    PubMed     Abstract available


  223. SANDERS AE
    A Century-Old Problem: Cognition and Neuropsychiatric Symptoms in Alzheimer Disease.
    Neurology. 2021 Aug 20. pii: WNL.0000000000012616.
    PubMed    


  224. EIKELBOOM WS, van den Berg E, Singleton EH, Baart SJ, et al
    Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.
    Neurology. 2021 Aug 19. pii: WNL.0000000000012598.
    PubMed     Abstract available


  225. LI J
    Alzheimer's Villanelle.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012612.
    PubMed    


  226. PETERSEN RC
    Mild Cognitive Impairment Criteria in Alzheimer's Disease Neuroimaging Initiative: Meeting Biological Expectations.
    Neurology. 2021 Aug 2. pii: WNL.0000000000012588.
    PubMed    


    July 2021
  227. TAO Q, Alvin Ang TF, Akhter-Khan SC, Itchapurapu IS, et al
    Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous Apolipoprotein E varepsilon4 Carriers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012512.
    PubMed     Abstract available


  228. BOCANCEA DI, Catharina van Loenhoud A, Groot C, Barkhof F, et al
    Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012499.
    PubMed     Abstract available


  229. GROTHE MJ, Moscoso A, Ashton NJ, Karikari TK, et al
    Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012513.
    PubMed     Abstract available


  230. POGGESI A
    Resilience and Resistance in Aging and Alzheimer Disease: Another Step to Fill the Gap Between Clinicians and Researchers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012500.
    PubMed    


  231. WILSON RS, Wang T, Yu L, Grodstein F, et al
    Cognitive Activity and Onset Age of Incident Alzheimer Disease Dementia.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012388.
    PubMed     Abstract available


  232. SALLOWAY S, Cummings J
    Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease.
    Neurology. 2021 Jul 7. pii: WNL.0000000000012451.
    PubMed    


    June 2021
  233. BUCIUC M, Duffy JR, Machulda MM, Graff-Radford J, et al
    Clinical, Imaging, and Pathologic Characteristics of Patients With Right Versus Left Hemisphere-Predominant Logopenic Progressive Aphasia.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012322.
    PubMed     Abstract available


  234. JUTTEN RJ, Sikkes SAM, Van der Flier WM, Scheltens P, et al
    Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.
    Neurology. 2021;96:e2673-e2684.
    PubMed     Abstract available


  235. BUCKLEY RF, Knopman DS
    Cognitive Heterogeneity in Alzheimer Clinical Trials: Harnessing Noise to Achieve Meaningfulness.
    Neurology. 2021;96:1017-1018.
    PubMed    


    May 2021
  236. HUGHES TM, Hajjar I
    Is Late-onset Alzheimer Disease Spelled "ATV(N)"?
    Neurology. 2021 May 24. pii: WNL.0000000000012259.
    PubMed    


  237. DONADIO V, Wang Z, Incensi A, Rizzo G, et al
    In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
    Neurology. 2021;96:e2513-e2524.
    PubMed     Abstract available


  238. FRIEDMAN LG, McKeehan N, Hara Y, Cummings JL, et al
    Value-Generating Exploratory Trials in Neurodegenerative Dementias.
    Neurology. 2021;96:944-954.
    PubMed     Abstract available


  239. MAYBLYUM DV, Becker JA, Jacobs HIL, Buckley RF, et al
    Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.
    Neurology. 2021 May 5. pii: WNL.0000000000012108.
    PubMed     Abstract available


  240. BALLARINI T, Melo van Lent D, Brunner J, Schroder A, et al
    Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age.
    Neurology. 2021 May 5. pii: WNL.0000000000012067.
    PubMed     Abstract available


  241. BELLAVER B, Ferrari-Souza JP, Uglione da Ros L, Carter SF, et al
    Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021 May 5. pii: WNL.0000000000012109.
    PubMed     Abstract available


  242. HAZRATI LN, Schwab N
    Embracing the Unknown in the Diagnosis of Traumatic Encephalopathy Syndrome.
    Neurology. 2021;96:835-836.
    PubMed    


    April 2021
  243. BOERWINKLE AH, Wisch JK, Chen CD, Gordon BA, et al
    Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012123.
    PubMed     Abstract available


  244. KARCESKI S
    The Effects of Long-term Medication Use in Alzheimer Disease.
    Neurology. 2021;96:e2247-e2250.
    PubMed    


  245. XU H, Garcia-Ptacek S, Jonsson L, Wimo A, et al
    Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Neurology. 2021;96:e2220-e2230.
    PubMed     Abstract available


  246. ROBERTS G, Durcan Mrcpi R, Donaghy PC, Lawley S, et al
    Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012060.
    PubMed     Abstract available


  247. HAMILTON CA, Matthews FE, Donaghy PC, Taylor JP, et al
    Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease.
    Neurology. 2021 Apr 19. pii: WNL.0000000000012024.
    PubMed     Abstract available


  248. HOWARD E, Irwin DJ, Rascovsky K, Nevler N, et al
    Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
    Neurology. 2021;96:e1855-e1864.
    PubMed     Abstract available


    March 2021
  249. QIAN J, Betensky RA, Hyman BT, Serrano-Pozo A, et al
    Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.
    Neurology. 2021 Mar 26. pii: WNL.0000000000011883.
    PubMed     Abstract available


  250. GOTTESMAN RF, Hamilton R
    Recruiting Diverse Populations in Clinical Trials: How Do We Overcome Selection Bias?
    Neurology. 2021;96:509-510.
    PubMed    


  251. KANG SH, Kim ME, Jang H, Kwon H, et al
    Amyloid Positivity in Alzheimer/Subcortical-Vascular Spectrum.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011833.
    PubMed     Abstract available


  252. SMIRNOV DS, Galasko D, Hiniker A, Edland S, et al
    Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011772.
    PubMed     Abstract available


  253. BARKHOF BF, Pressman PS
    Time Is of the Essence: Early Detection of Incipient Alzheimer Pathology.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011739.
    PubMed    


    February 2021
  254. ROBINSON-PAPP J, Saylor D
    HIV in the Brain: From Devastating Dementia to White Matter Hyperintensities.
    Neurology. 2021 Feb 26. pii: WNL.0000000000011735.
    PubMed    


  255. HUYNH K, Piguet O, Kwok J, Dobson-Stone C, et al
    Clinical and Biological Correlates of White Matter Hyperintensities in Patients with Behavioral-variant Frontotemporal Dementia and Alzheimer Disease.
    Neurology. 2021 Feb 17. pii: WNL.0000000000011638.
    PubMed     Abstract available


  256. THERRIAULT J, Pascoal TA, Benedet AL, Tissot C, et al
    Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;96:e975-e985.
    PubMed     Abstract available


  257. RENTZ DM, Papp KV, Mayblyum DV, Sanchez JS, et al
    Association of Digital Clock Drawing with PET Amyloid and Tau Pathology in Normal Older Adults.
    Neurology. 2021 Feb 15. pii: WNL.0000000000011697.
    PubMed     Abstract available


  258. DETERS K, Napolioni V, Sperling RA, Greicius MD, et al
    Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
    Neurology. 2021 Feb 10. pii: WNL.0000000000011599.
    PubMed     Abstract available


  259. FERREIRA D, Nordberg A, Westman E
    Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:238.
    PubMed    


  260. ULEMAN JF, Melis RJF, Olde Rikkert MGM
    Reader Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237-238.
    PubMed    


  261. GANESH A, Galetta S
    Editors' Note: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237.
    PubMed    


    January 2021
  262. JOSEPH-MATHURIN N, Wang G, Kantarci K, Jack CR Jr, et al
    Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease.
    Neurology. 2021 Jan 25. pii: WNL.0000000000011542.
    PubMed     Abstract available


  263. SAJJADI SA, Ash S, Cappa S
    Glass half full: Preservation of memory in Alzheimer-related primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011404.
    PubMed    


  264. MESULAM MM, Coventry C, Kuang A, Bigio EH, et al
    Memory resilience in Alzheimer's disease with primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011397.
    PubMed     Abstract available


  265. BLAZHENETS G, Frings L, Ma Y, Sorensen A, et al
    Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011521.
    PubMed     Abstract available


  266. JAGUST WJ, Landau SM
    Temporal Dynamics of Beta-amyloid Accumulation in Aging and Alzheimer's Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011524.
    PubMed     Abstract available


  267. TRELLE AN, Carr VA, Wilson EN, Swarovski MS, et al
    Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011477.
    PubMed     Abstract available


  268. THERRIAULT J, Pascoal TA, Savard M, Benedet AL, et al
    Topographic Distribution of Amyloid-beta, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease.
    Neurology. 2021;96:e81-e92.
    PubMed     Abstract available


    December 2020
  269. KNOPMAN DS, Jagust WJ
    Alzheimer Disease Spectrum: Syndrome and Etiology from Clinical and PET Imaging Perspectives.
    Neurology. 2020 Dec 22. pii: WNL.0000000000011415.
    PubMed    


  270. KOYAMA AK, Irwin DJ
    Alzheimer disease biomarker profiles in dementia with Lewy bodies: Does A plus T spell D-L-B?
    Neurology. 2020;95:1076-1077.
    PubMed    


  271. GICAS KM, Honer WG, Wilson RS, Boyle PA, et al
    Association of serial position scores on memory tests and hippocampal-related neuropathologic outcomes.
    Neurology. 2020;95:e3303-e3312.
    PubMed     Abstract available


  272. PETTIGREW C, Soldan A, Wang J, Wang MC, et al
    Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline.
    Neurology. 2020;95:e3093-e3103.
    PubMed     Abstract available


  273. PALMQVIST S, Eshaghi A
    Spatial distribution of tau and beta-amyloid pathologies and their role in different Alzheimer's disease phenotypes.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011272.
    PubMed    


  274. LA JOIE R, Visani AV, Lesman-Segev OH, Baker SL, et al
    Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011270.
    PubMed     Abstract available


    November 2020
  275. KARCESKI S
    How a buildup of abnormal proteins in the brain may be the key to understanding Alzheimer disease.
    Neurology. 2020;95:e2951-e2953.
    PubMed    


  276. YOUNAN D, Wang X, Casanova R, Barnard R, et al
    PM2.5 associated with gray matter atrophy reflecting increased Alzheimers risk in older women.
    Neurology. 2020 Nov 18. pii: WNL.0000000000011149.
    PubMed     Abstract available


  277. ILLAN-GALA I, Lleo A, Karydas A, Staffaroni AM, et al
    Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease.
    Neurology. 2020 Nov 16. pii: WNL.0000000000011226.
    PubMed     Abstract available


  278. GRAFF-RADFORD J, Knopman D, Jones D
    Author response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:846.
    PubMed    


  279. ALLALI G, Laticevschi T
    Reader response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845-846.
    PubMed    


  280. SIEGLER JE 3RD, Galetta S
    Editors' note: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845.
    PubMed    


    October 2020
  281. KIM HR, Lee T, Choi JK, Jeong Y, et al
    Genetic variants beyond amyloid and tau associated with cognitive decline: A cohort study.
    Neurology. 2020;95:e2366-e2377.
    PubMed     Abstract available


  282. WEIGAND AJ, Bondi MW, Thomas KR, Campbell NL, et al
    Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
    Neurology. 2020;95:e2295-e2304.
    PubMed     Abstract available


  283. KERCHNER GA, Filippi M
    Abeta-PET pathology accumulation index: Ready for the clinic?
    Neurology. 2020 Oct 19. pii: WNL.0000000000011060.
    PubMed    


  284. LEUZY A, Lilja J, Buckley CJ, Ossenkoppele R, et al
    Derivation and utility of an Abeta-PET pathology accumulation index to estimate Abeta load.
    Neurology. 2020 Oct 19. pii: WNL.0000000000011031.
    PubMed     Abstract available


  285. BENNETT DA, Knopman DS
    Extending Alzheimer disease biomarker studies into the Hispanic community.
    Neurology. 2020;95:665-666.
    PubMed    


  286. NAG S, Barnes LL, Yu L, Wilson RS, et al
    Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents.
    Neurology. 2020;95:e2056-e2064.
    PubMed     Abstract available


  287. GERTJE EC, van Westen D, Panizo C, Mattsson-Carlgren N, et al
    Association of enlarged perivascular spaces and measures of small vessel and Alzheimers disease.
    Neurology. 2020 Oct 12. pii: WNL.0000000000011046.
    PubMed    


  288. KAPASI A, Yu L, Boyle PA, Barnes LL, et al
    Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging.
    Neurology. 2020;95:e1951-e1962.
    PubMed     Abstract available


  289. CATRICALA E, Polito C, Presotto L, Esposito V, et al
    Neural correlates of naming errors across different neurodegenerative diseases: A FDG-PET study.
    Neurology. 2020 Oct 1. pii: WNL.0000000000010967.
    PubMed     Abstract available


    September 2020
  290. HANES J, Kovac A, Kvartsberg H, Kontsekova E, et al
    Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias.
    Neurology. 2020 Sep 24. pii: WNL.0000000000010814.
    PubMed     Abstract available


  291. BRENOWITZ WD, Besser LM, Kukull WA, Keene CD, et al
    Clinician-judged hearing impairment and associations with neuropathologic burden.
    Neurology. 2020;95:e1640-e1649.
    PubMed     Abstract available


  292. SCHREIBER S, DiFrancesco JC
    Impaired occipital cerebrovascular reactivity as a biomarker for vascular beta-amyloid.
    Neurology. 2020;95:415-416.
    PubMed    


  293. GUZMAN-VELEZ E, Martinez J, Papp K, Baena A, et al
    Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.
    Neurology. 2020;95:e1312-e1321.
    PubMed     Abstract available


    August 2020
  294. KIM JW, Byun MS, Lee JH, Yi D, et al
    Serum albumin and beta-amyloid deposition in the human brain.
    Neurology. 2020;95:e815-e826.
    PubMed     Abstract available


  295. VAN DER ZANDE JJ, Gouw AA, van Steenoven I, van de Beek M, et al
    Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
    Neurology. 2020;95:e662-e670.
    PubMed     Abstract available


    July 2020
  296. COLLIJ LE, Heeman F, Salvado G, Ingala S, et al
    Multi-tracer model for staging cortical amyloid deposition using PET imaging.
    Neurology. 2020 Jul 16. pii: WNL.0000000000010256.
    PubMed     Abstract available


  297. EBENAU JL, Timmers T, Wesselman LMP, Verberk IMW, et al
    ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
    Neurology. 2020;95:e46-e58.
    PubMed     Abstract available


  298. SAKAE N, Santos OA, Pedraza O, Litvan I, et al
    Clinical and pathologic features of cognitive-predominant corticobasal degeneration.
    Neurology. 2020;95:e35-e45.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.